RKRebecca E. Kotcher

Rebecca E. Kotcher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca E. Kotcher has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Maria R. Mascarenhas

    Division of Gastroenterology, Hepatology and Nutrition, Integrative Health Program, Children's Hospital of Philadelphia, Philadelphia, PA, United States

    2 shared publications
  • Beverly S. Emanuel

    Perelman School of Medicine University of Pennsylvania PA

    1 shared publication
  • Daniel B. Chait

    Perelman School of Medicine University of Pennsylvania PA

    1 shared publication
  • Donna M. McDonald‐McGinn

    Perelman School of Medicine University of Pennsylvania PA

    1 shared publication
  • Elaine H. Zackai

    Perelman School of Medicine University of Pennsylvania PA

    1 shared publication
  • Hsing-Hua Sylvia Lin

    Department of Anesthesiology & Perioperative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    1 shared publication

Latest Publications

  • Open Access

    Blue Light as an Anti-inflammatory and Analgesic Strategy in Thoracic Trauma (BLAASTT): protocol for a randomised controlled trial in adult trauma inpatients with painful rib fractures

    by Rebecca E Kotcher, Matthew R Rosengart, Luca La Colla, Hsing-Hua Sylvia Lin, Keith M Vogt, Yan Xu, Matthew D Neal

    Introduction: Blue light (peak wavelength 442 nm) has been shown to modulate the immune response in preclinical models of intra-abdominal sepsis and pneumonia. In vivo pathways involve optic nerve stimulation with transmission to the central nervous system, activation of parasympathetic pathways terminating at the spleen, and downstream immune effects including decreased inflammatory tissue damage and improved pathogen clearance. Related effects on pain mediators including proinflammatory cytokines (interleukin 6, TNF- α) and autonomic tone (increased parasympathetic outflow) suggest possible analgesic properties that would be highly relevant to a trauma population. Methods and analysis: This is a randomised controlled trial in which adult trauma inpatients (≥18 years) with painful rib fractures will be allocated 1:1:1 to three arms: bright blue light intervention (peak 442 nm, ~1400 lux), bright full-spectrum light comparison (~1400 lux) and usual ambient light control. Bright light exposures will be administered for 4 consecutive hours daily for up to 3 days. The primary outcome will be any measurable changes in chest wall pain intensity during deep breathing, quantified using an 11-point Numerical Rating Scale. Secondary outcomes will assess chest wall pain intensity at rest, opioid requirements, delirium incidence, pulmonary complication incidence, hospital-free and intensive care unit-free days, and physiological markers of autonomic nervous system, circadian, and immune activation. Sample size analysis yields a total of 75 participants needed to detect a 2-point difference in pain scores with >80% power and assuming a 20% non-completion rate. Ethics and dissemination: Full ethical approval for this trial has been granted by the University of Pittsburgh Institutional Review Board. On study completion, results will be published in the peer-reviewed literature and at ClinicalTrials.gov. Trial registration number: NCT06626334.


  • Gastrointestinal Features of 22q11.2 Deletion Syndrome Include Chronic Motility Problems From Childhood to Adulthood

    by Rebecca E. Kotcher, Daniel B. Chait, Jason M. Heckert, T. Blaine Crowley, Kimberly A. Forde, Nitin K. Ahuja, Maria R. Mascarenhas, Beverly S. Emanuel, Elaine H. Zackai, Donna M. McDonald‐McGinn, et al.

    Objectives: 22q11.2 deletion syndrome (22q11.2DS) is the most common chromosomal microdeletion syndrome and has a multisystemic presentation including gastrointestinal features that have not yet been fully described. Our aim was to examine lifetime gastrointestinal problems in a large cohort of patients with 22q11.2DS.Methods: All patients followed in the 22q and You Center at the Children's Hospital of Philadelphia (n = 1421) were retrospectively screened for: 1) age ≥ 17 years, 2) documented chromosomal microdeletion within the 22q11.2 LCR22A‐LCR22D region, and 3) sufficient clinical data to characterize the adult gastrointestinal phenotype. Gastrointestinal problems in childhood, adolescence, and adulthood were summarized. Statistical association testing of symptoms against other patient characteristics was performed.Results: Included patients (n = 206; 46% female; mean age, 27 years; median follow‐up, 21 years) had similar clinical characteristics to the overall cohort. Genetic distribution was also similar, with 96% having deletions including the critical LCR22A‐LCR22B segment (95% in the overall cohort). Most patients experienced chronic gastrointestinal symptoms in their lifetime (91%), but congenital gastrointestinal malformations (3.5%) and gastrointestinal autoimmune diseases (1.5%) were uncommon. Chronic symptoms without anatomic or pathologic abnormalities represented the vast burden of illness. Chronic symptoms in adulthood are associated with other chronic gastrointestinal symptoms and psychiatric comorbidities (P < 0.01) but not with deletion size or physiologic comorbidities (P > 0.05). One exception was increased nausea/vomiting in hypothyroidism (P = 0.002).Conclusions: Functional gastrointestinal disorders (FGIDs) are a common cause of ill health in children and adults with 22q11.2DS. Providers should consider screening for the deletion in patients presenting with FGIDs and associated comorbidities such as neuropsychiatric illness, congenital heart disease, and palatal abnormalities.